Country
Full text data for US,EP,CN
Type
Legal Validity
Legal Status
Filing Date
Publication Date
Inventor
Assignee
Click to expand
IPC(Section)
IPC(Class)
IPC(Subclass)
IPC(Group)
IPC(Subgroup)
Agent
Agency
Claims Number
Figures Number
Citation Number of Times
Assignee Number
No. Publication Number Title Publication/Patent Number Publication/Patent Number Publication Date Publication Date
Application Number Application Number Filing Date Filing Date
Inventor Inventor Assignee Assignee IPC IPC
1
US2021093617A1
Method of Treating Cancer With Atpenin A5 Derviatives
Publication/Patent Number: US2021093617A1 Publication Date: 2021-04-01 Application Number: 17/054,235 Filing Date: 2019-05-09 Inventor: Trippier, Paul   Brookes, Paul   Assignee: Texas Tech University System   IPC: A61K31/44 Abstract: The present invention includes molecules, composition, and methods for making and using a molecule having the formula (I), wherein R′ is selected from H, methoxy, or methoxymethyl; X is selected from H, OH, methoxy, or methoxymethyl or O—O methoxymethyl; Y is O; and R″ is selected from H, OH, 2-furan, ethyl, propyl, pentyl, hexyl, heptyl, octyl, nonly, decyl, or dodecyl, that are saturated or unsaturated.
2
EP3787750A1
METHODS FOR REDUCING ACCUMULATED PATHOLOGIC TAU PROTEIN
Publication/Patent Number: EP3787750A1 Publication Date: 2021-03-10 Application Number: 19723991.6 Filing Date: 2019-05-01 Inventor: Kopke, Richard D.   Assignee: Hough Ear Institute   IPC: A61P27/16
3
US10888551B2
Drug delivery system
Publication/Patent Number: US10888551B2 Publication Date: 2021-01-12 Application Number: 15/763,845 Filing Date: 2017-02-23 Inventor: Poojari, Radhika   Panda, Dulal   Srivastava, Rohit   Assignee: INDIAN INSTITUTE OF TECHNOLOGY, BOMBAY   IPC: A61K31/44 Abstract: The present invention provides for a drug delivery system for anti-cancer compound and method of preparation thereof.
4
US2021059995A1
Composition for Protecting Cornea
Publication/Patent Number: US2021059995A1 Publication Date: 2021-03-04 Application Number: 16/957,757 Filing Date: 2018-12-26 Inventor: Ikeda, Hanako   Kakizuka, Akira   Kinoshita, Shigeru   Nakamura, Takahiro   Nagata, Maho   Koizumi, Noriko   Okumura, Naoki   Assignee: Kyoto University   Kyoto Prefectural Public University Corporation   The Doshisha   IPC: A61K31/44 Abstract: The inventors have found that VCP inhibitors protect corneal endothelial cells and corneal epithelial cells. Accordingly, the disclosure provides a composition for protecting a cornea comprising a compound of formula (I) or an ester, oxide, pharmaceutically acceptable salt or solvate thereof. In another aspect the disclosure provides a composition for treating and/or preventing a corneal disease comprising a compound of formula (I). In a further aspect the disclosure provides a composition for ocular irrigation comprising a compound of formula (I). In a still further aspect the disclosure provides a composition for preserving a corneal graft comprising a compound of formula (I).
5
US10898500B2
Combination of regorafenib and acetylsalicylic acid for treating cancer
Publication/Patent Number: US10898500B2 Publication Date: 2021-01-26 Application Number: 14/431,119 Filing Date: 2013-09-23 Inventor: Weber, Olaf   Ziegelbauer, Karl   Assignee: BAYER PHARMA AKTIENGESELLSCHAFT   BAYER AG   IPC: A61K31/616 Abstract: The present invention relates to pharmaceutical compositions and combinations comprising regorafenib and acetylsalicylic acid, or a hydrate, solvate, metabolite or pharmaceutically acceptable salt thereof or a polymorph thereof for treating, preventing or managing diseases and conditions including hyperproliverative disorders such as cancer in humans and other mammals.
6
CN108785306B
索拉非尼在制备抑菌及干预致病菌生物被膜的药物中的用途
Grant
Publication/Patent Number: CN108785306B Publication Date: 2021-02-19 Application Number: 201811047450.0 Filing Date: 2018-09-09 Inventor: 李艳华   崔文强   周永辉   屈谦伟   王金鹏   Assignee: 东北农业大学   IPC: A61K31/44 Abstract: 本发明公开了索拉非尼在抑菌及干预致病菌生物被膜中的用途,属于索拉非尼的新医药用途领域。本发明人发现索拉非尼除了具有抗肿瘤活性之外,还具有确切的抑制木糖葡萄球菌生长以及干预木糖葡萄球菌生物被膜形成的药理活性。本发明通过体内、体外试验证明索拉非尼不仅是一个多靶点抗肿瘤药物,具有抗菌作用且能够有效干预木糖葡萄球生物被膜的形成,能应用于抑制木糖葡萄球菌、干预木糖葡萄球菌生物被膜形成以及治疗奶牛乳房炎等方面。
7
EP3758702A1
TREATMENT OF HEREDITARY ANGIOEDEMA
Publication/Patent Number: EP3758702A1 Publication Date: 2021-01-06 Application Number: 19760469.7 Filing Date: 2019-02-28 Inventor: Mcdonald, Andrew   Qian, Shawn   Kalfus, Ira   Assignee: Lifesci Pharmaceuticals, Inc.   IPC: A61K31/44
8
US2021008047A1
TARGETING MINIMAL RESIDUAL DISEASE IN CANCER WITH RXR ANTAGONISTS
Publication/Patent Number: US2021008047A1 Publication Date: 2021-01-14 Application Number: 16/969,282 Filing Date: 2019-02-13 Inventor: Marine, Jean-christophe   Rambow, Florian   Assignee: VIB VZW   KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D   IPC: A61K31/44 Abstract: The invention relates to the field of tumor treatment, in particular to melanoma tumor treatment. In particular it relates to the use of retinoid X receptor antagonists for use in tumor treatment, in particular for use in reducing tumor cell heterogeneity during minimal residual disease (MRD), and thus for use in treating MRD. Even more in particular, the invention relates to the use of retinoid X receptor antagonists in combination with clinically established treatments such as treatment with a combination of BRAF and MEK inhibitors, and optionally other anticancer agents.
9
EP3600307B1
COMPOSITIONS FOR USE IN METHODS OF INHIBITING PROTEIN KINASES
Publication/Patent Number: EP3600307B1 Publication Date: 2021-05-05 Application Number: 18718334.8 Filing Date: 2018-03-29 Inventor: Cuny, Gregory   Suebsuwong, Chalada   Degterev, Alexei   Assignee: University of Houston System   Trustees of Tufts College   IPC: A61K31/44
10
US2021052560A1
USE OF PRIDOPIDINE FOR TREATING FUNCTIONAL DECLINE
Publication/Patent Number: US2021052560A1 Publication Date: 2021-02-25 Application Number: 17/019,346 Filing Date: 2020-09-13 Inventor: Hayden, Michael   Geva, Michal   Assignee: PRILENIA NEUROTHERAPEUTICS LTD.   IPC: A61K31/44 Abstract: This invention provides a method of maintaining functional capacity, improving functional capacity, or lessening the decline of functional capacity in a human patient comprising periodically orally administering to the patient a pharmaceutical composition comprising pridopidine such that a dose of 90 mg of pridopidine is administered to the patient per day, so as to thereby maintain functional capacity, improve functional capacity, or lessen the decline of functional capacity in the human patient.
11
US2021003573A1
MARKER FOR IDENTIFYING PATIENTS WITH GLIOBASTOMA WHO RESPOND POSITIVELY TO THE DRUG REGORAFENIB
Publication/Patent Number: US2021003573A1 Publication Date: 2021-01-07 Application Number: 16/980,122 Filing Date: 2019-03-12 Inventor: Indraccolo, Stefano   De, Salvo Gian Luca   Lombardi, Giuseppe   Assignee: ISTITUTO ONCOLOGICO VENETO IOV-IRCCS   IPC: G01N33/574 Abstract: The present invention relates to a marker for allowing the identification of patients with glioblastoma who respond positively to the drug Regorafenib.
12
US10933076B2
Crocin-sorafenib combination therapy for liver cancer
Publication/Patent Number: US10933076B2 Publication Date: 2021-03-02 Application Number: 16/513,026 Filing Date: 2019-07-16 Inventor: Amin, Amr   Awad, Basma   Assignee: UNITED ARAB EMIRATES UNIVERSITY   IPC: A61K31/7024 Abstract: A therapeutic combination of drugs for the treatment of a liver cancer includes a crocin, or a pharmaceutically acceptable pro-drug thereof, and sorafenib. A method of treating, suppressing, or reducing the severity of a liver cancer in a subject, involves administering to the subject a first amount of sorafenib, and administering to the subject a second amount of a crocin or a pharmaceutically acceptable pro-drug thereof.
13
EP2434891B9
METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS
Publication/Patent Number: EP2434891B9 Publication Date: 2021-05-05 Application Number: 10781238.0 Filing Date: 2010-05-27 Inventor: Almstead, Neil   Arasu, Tamil   Choi, Soongyu   Cao, Liangxian   Campbell, Jeff   Corson, Don   Davis, Thomas W.   Graci, Jason D.   Gu, Zhengxian   Hwang, Peter Seongwoo   Lennox, William   Miao, Harry H.   Miller, Langdon   Moon, Young-choon   Qi, Hongyan   Trotta, Christopher   Weetall, Marla L.   Assignee: PTC Therapeutics, Inc.   IPC: A01N43/42
14
US2021015804A1
FORMULATIONS OF (S)-3-AMINO-6-METHOXY-N-(3,3,3-TRIFLUORO-2-HYDROXY-2-METHYLPROPYL)-5-(TRIFLUOROMETHYL)PICOLINAMIDE
Publication/Patent Number: US2021015804A1 Publication Date: 2021-01-21 Application Number: 16/929,472 Filing Date: 2020-07-15 Inventor: Dubey, Vivek   Lowalekar, Rohit   Santos, Paulo G.   Thoma, Hubert   Tian, Xianbin   Assignee: NOVARTIS AG   IPC: A61K31/44 Abstract: Provided herein are compounds and pharmaceutical compositions useful for treating bronchiectasis, chronic obstructive pulmonary disorder, cystic fibrosis, chronic bronchitis or asthma comprising administering to a subject in need thereof a therapeutically effective amount of a compound or pharmaceutical composition described herein.
15
US2021015835A1
CROCIN-SORAFENIB COMBINATION THERAPY FOR LIVER CANCER
Publication/Patent Number: US2021015835A1 Publication Date: 2021-01-21 Application Number: 16/513,026 Filing Date: 2019-07-16 Inventor: Amin, Amr   Awad, Basma   Assignee: United Arab Emirates University   IPC: A61K31/7024 Abstract: A therapeutic combination of drugs for the treatment of a liver cancer includes a crocin, or a pharmaceutically acceptable pro-drug thereof, and sorafenib. A method of treating, suppressing, or reducing the severity of a liver cancer in a subject, involves administering to the subject a first amount of sorafenib, and administering to the subject a second amount of a crocin or a pharmaceutically acceptable pro-drug thereof.
16
EP3782622A1
ADENOSINE A2B RECEPTOR AGONIST FOR THE TREATMENT OF MUSCULOSKELETAL CONDITIONS
Publication/Patent Number: EP3782622A1 Publication Date: 2021-02-24 Application Number: 20191883.6 Filing Date: 2020-08-20 Inventor: Pfeifer, Prof. Dr. Alexander   Fleischmann, Prof. Dr. Bernd   Wenzel, Dr. Daniela   Naumann, Dr. Jennifer   Haufs-brusberg, Dr. Saskia   Hochhäuser, Dr. Aileen   Reverte-salisa, Dr. Laia   Copperi, Francesca   Gnad, Dr. Thorsten   Assignee: Rheinische Friedrich-Wilhelms-Universität Bonn   IPC: A61K31/44 Abstract: Die vorliegende Erfindung betrifft neue Behandlungsstrategien von Krankheiten des Muskel-Skelett-Systems und des Bindegewebes, insbesondere von Sarkopenie, welche auf der Aktivierung des Adenosin-A2B-Rezeptors basieren.
17
US2021113470A1
NOVEL AMORPHOUS DISPERSION OF CYCLOPROPANECARBOXYLIC ACID (5-{5-[N'-(2-CHLORO-6-METHYLBENZOYL) HYDRAZINOCARBONYL] -2-METHYL-PHENYLETHYNYL}-PYRIDIN-2-YL) AMIDE
Publication/Patent Number: US2021113470A1 Publication Date: 2021-04-22 Application Number: 16/494,598 Filing Date: 2018-03-15 Inventor: Zala, Yashoraj   Hanamannavar, Bramhanand   Dharmadhikari, Nitin   Assignee: SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED   IPC: A61K9/16 Abstract: An oral, solid dosage form comprising a mixture of compound of formula I and a fusible polymeric carrier; and optionally pharmaceutically pp acceptable excipients, wherein the mixture is an amorphous dispersion.
18
EP3810574A1
PROCESS FOR MAKING AMINO DIARYL ETHERS AND AMINO DIARYL ETHERS HYDROCHLORIDE SALTS
Publication/Patent Number: EP3810574A1 Publication Date: 2021-04-28 Application Number: 19737475.4 Filing Date: 2019-06-20 Inventor: Bauer, Michael   Hahn, Uwe   Bappert, Erhard   Assignee: Cellestia Biotech AG   IPC: C07D213/73
19
US10912777B2
Dipyridamole for use in treating SLC29A2 nuclear-expressing cancer
Publication/Patent Number: US10912777B2 Publication Date: 2021-02-09 Application Number: 16/470,952 Filing Date: 2017-12-19 Inventor: Jou, Yuh-shan   Shen, Roger   Assignee: ACADEMIA SINICA   IPC: A61K31/519 Abstract: A pharmaceutical composition comprising (i) a therapeutically effective amount of an inhibitor of the oncogene SLC29A2; and (ii) a pharmaceutically acceptable carrier, for use in suppressing proliferation, occurrence, and metastasis of cancer cells overexpressing the oncogene SLC29A2 in a cancer patient, and/or prolonging cancer patient survival. The inhibitor of the oncogene SLC29A2 may be at least one selected from the group consisting of dipyridamole, dilazep, draflzine, nitorbenzylthioinosine, and the derivatives thereof. The composition for use may further comprise sorafenib for the same use.
20
US2021015805A1
TREATMENT FOR PARKINSON'S DISEASE
Publication/Patent Number: US2021015805A1 Publication Date: 2021-01-21 Application Number: 17/061,139 Filing Date: 2020-10-01 Inventor: Damle, Nitin Krishnaji   Mandhane, Sanjay Nandlalji   Upadhya, Manoj Atmaramji   Mehetre, Sameer Vishwanath   Chidrewar, Gajanan Uttamrao   Sengupta, Prabal   Chitturi, Trinadha Rao   Assignee: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.   IPC: A61K31/44 Abstract: The invention relates to a method of treating or preventing Parkinson's disease in a subject comprising administering a compound of Formula I wherein, R1 is —NHC(O) C3-6 cycloalkyl and R2 is hydrogen; or R1 and R2 along with the carbon atoms to which they are attached form a six membered aromatic ring, wherein the ring is substituted with one or more groups selected from hydrogen, halogen and C1-6 alkyl; R3 and R4 are independently selected from group comprising hydrogen, halogen, C1-3 alkyl, OC1-3 alkyl, NO2, SC1-3 alkyl, C1-3 haloalkyl, OC1-3 haloalkyl, and SC1-3 haloalkyl; or a pharmaceutically acceptable salt thereof.
Total 500 pages